Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Schepisi

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|July 17, 2020
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancerVincenza Conteduca, Daniel Wetterskog, Emanuela Scarpi, et al.
Urologic Oncology|February 7, 2018
Association among metabolic syndrome, inflammation, and survival in prostate cancerVincenza Conteduca, Orazio Caffo, Luca Galli, et al.
Frontiers in Endocrinology|June 14, 2019
Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver SupportSilvia De Padova, Chiara Casadei, Alejandra Berardi, et al.
International Journal of Cancer|October 4, 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patientsVincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, et al.
The Oncologist|May 16, 2025
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancerVincenza Conteduca, Emanuela Scarpi, Alice Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2026
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose ChemotherapyMilena Urbini, Thomas F Eleveld, Maurizio Polano, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker studyVincenza Conteduca, Daniel Wetterskog, Elena Castro, et al.
Journal of Clinical Medicine|June 26, 2020
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted TherapyVincenza Conteduca, Orazio Caffo, Emanuela Scarpi, et al.
Prostate Cancer and Prostatic Diseases|March 13, 2026
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapySara Bleve, Francesco Ravera, Silvia Rodrigues, et al.
European Urology Open Science|February 22, 2024
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 StudyChiara Casadei, Emanuela Scarpi, Vincenza Conteduca, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|July 17, 2020
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancerVincenza Conteduca, Daniel Wetterskog, Emanuela Scarpi, et al.
Urologic Oncology|February 7, 2018
Association among metabolic syndrome, inflammation, and survival in prostate cancerVincenza Conteduca, Orazio Caffo, Luca Galli, et al.
Frontiers in Endocrinology|June 14, 2019
Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver SupportSilvia De Padova, Chiara Casadei, Alejandra Berardi, et al.
International Journal of Cancer|October 4, 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patientsVincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, et al.
The Oncologist|May 16, 2025
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancerVincenza Conteduca, Emanuela Scarpi, Alice Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2026
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose ChemotherapyMilena Urbini, Thomas F Eleveld, Maurizio Polano, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker studyVincenza Conteduca, Daniel Wetterskog, Elena Castro, et al.
Journal of Clinical Medicine|June 26, 2020
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted TherapyVincenza Conteduca, Orazio Caffo, Emanuela Scarpi, et al.
Prostate Cancer and Prostatic Diseases|March 13, 2026
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapySara Bleve, Francesco Ravera, Silvia Rodrigues, et al.
European Urology Open Science|February 22, 2024
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 StudyChiara Casadei, Emanuela Scarpi, Vincenza Conteduca, et al.
Pageof 7